One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi

Cecilia Kanyama; S. F. Molloy; Adrienne K. Chan; Duncan Lupiya; Chimwemwe Chawinga; Jack Adams; Philip Bright; David Lalloo; Robert S. Heyderman; Olivier Lortholary; Shabbar Jaffar; Angela Loyse; Joep J. Van Oosterhout; Mina C. Hosseinipour; Thomas S. Harrison

doi:10.1093/cid/ciz454

One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi

Cecilia Kanyama
, S. F. Molloy
, Adrienne K. Chan
, Duncan Lupiya
, Chimwemwe Chawinga
, Jack Adams
, Philip Bright
, David Lalloo
, Robert S. Heyderman
, Olivier Lortholary
, Shabbar Jaffar
, Angela Loyse
, Joep J. Van Oosterhout
, Mina C. Hosseinipour
, Thomas S. Harrison

University of North Carolina at Chapel Hill
City St George's, University of London
Ministry of Health, Malawi
University of Toronto
North Bristol NHS Trust
Malawi-Liverpool-Wellcome Trust Clinical Research Programme
Kamuzu University of Health Sciences
University College London
Centre national de la Recherche Scientifique
Université Paris Cité

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

In Malawi, 236 participants from the ACTA cryptococcal meningitis treatment trial were followed-up for 12 months. The trial outcomes reported at 10 weeks were sustained to 1 year. One-week amphotericinB plus flucytosine was associated with the lowest 1 year mortality (27.5% [95%CI: 16.3 to 44.1]).

Original language	English
Pages (from-to)	521-524
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	70
Issue number	3
Early online date	1 Jun 2019
DOIs	https://doi.org/10.1093/cid/ciz454
Publication status	Published - 1 Feb 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cryptococcal meningitis
HIV
Long-Term follow-up
Malawi
Treatment

Access to Document

10.1093/cid/ciz454Licence: CC BY

Ciz454Accepted author manuscript, 633 KBLicence: CC BY

Cite this

Kanyama, C., Molloy, S. F., Chan, A. K., Lupiya, D., Chawinga, C., Adams, J., Bright, P., Lalloo, D., Heyderman, R. S., Lortholary, O., Jaffar, S., Loyse, A., Van Oosterhout, J. J., Hosseinipour, M. C., & Harrison, T. S. (2020). One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi. Clinical Infectious Diseases, 70(3), 521-524. https://doi.org/10.1093/cid/ciz454

@article{037d4655c88240259d36a15b1c12ed9e,

title = "One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi",

abstract = "In Malawi, 236 participants from the ACTA cryptococcal meningitis treatment trial were followed-up for 12 months. The trial outcomes reported at 10 weeks were sustained to 1 year. One-week amphotericinB plus flucytosine was associated with the lowest 1 year mortality (27.5\% [95\%CI: 16.3 to 44.1]).",

keywords = "Cryptococcal meningitis, HIV, Long-Term follow-up, Malawi, Treatment",

author = "Cecilia Kanyama and Molloy, \{S. F.\} and Chan, \{Adrienne K.\} and Duncan Lupiya and Chimwemwe Chawinga and Jack Adams and Philip Bright and David Lalloo and Heyderman, \{Robert S.\} and Olivier Lortholary and Shabbar Jaffar and Angela Loyse and \{Van Oosterhout\}, \{Joep J.\} and Hosseinipour, \{Mina C.\} and Harrison, \{Thomas S.\}",

year = "2020",

month = feb,

day = "1",

doi = "10.1093/cid/ciz454",

language = "English",

volume = "70",

pages = "521--524",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "3",

}

Kanyama, C, Molloy, SF, Chan, AK, Lupiya, D, Chawinga, C, Adams, J, Bright, P, Lalloo, D, Heyderman, RS, Lortholary, O, Jaffar, S, Loyse, A, Van Oosterhout, JJ, Hosseinipour, MC & Harrison, TS 2020, 'One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi', Clinical Infectious Diseases, vol. 70, no. 3, pp. 521-524. https://doi.org/10.1093/cid/ciz454

TY - JOUR

T1 - One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi

AU - Kanyama, Cecilia

AU - Molloy, S. F.

AU - Chan, Adrienne K.

AU - Lupiya, Duncan

AU - Chawinga, Chimwemwe

AU - Adams, Jack

AU - Bright, Philip

AU - Lalloo, David

AU - Heyderman, Robert S.

AU - Lortholary, Olivier

AU - Jaffar, Shabbar

AU - Loyse, Angela

AU - Van Oosterhout, Joep J.

AU - Hosseinipour, Mina C.

AU - Harrison, Thomas S.

PY - 2020/2/1

Y1 - 2020/2/1

N2 - In Malawi, 236 participants from the ACTA cryptococcal meningitis treatment trial were followed-up for 12 months. The trial outcomes reported at 10 weeks were sustained to 1 year. One-week amphotericinB plus flucytosine was associated with the lowest 1 year mortality (27.5% [95%CI: 16.3 to 44.1]).

AB - In Malawi, 236 participants from the ACTA cryptococcal meningitis treatment trial were followed-up for 12 months. The trial outcomes reported at 10 weeks were sustained to 1 year. One-week amphotericinB plus flucytosine was associated with the lowest 1 year mortality (27.5% [95%CI: 16.3 to 44.1]).

KW - Cryptococcal meningitis

KW - HIV

KW - Long-Term follow-up

KW - Malawi

KW - Treatment

U2 - 10.1093/cid/ciz454

DO - 10.1093/cid/ciz454

M3 - Article

SN - 1058-4838

VL - 70

SP - 521

EP - 524

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 3

ER -

One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this